Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 81
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cephalalgia ; 40(9): 903-912, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32580575

RESUMO

BACKGROUND: Medication overuse is a significant issue that complicates the treatment of headache disorders. The most effective medications for the acute treatment of migraine all have the capacity to induce medication overuse headache (MOH). Novel acute migraine-specific treatments are being developed. However, because the mechanism(s) underlying medication overuse headache are not well understood, it is difficult to predict whether any particular acute medication will induce MOH in susceptible individuals. LY573144 (lasmiditan), a 5-HT1F receptor agonist, has recently been shown to be effective in the acute treatment of migraine in phase 3 trials. The aim of this study is to determine whether frequent administration of lasmiditan induces behaviors consistent with MOH in a pre-clinical rat model. METHODS: Sprague Dawley rats were administered six doses of lasmiditan (10 mg/kg), sumatriptan (10 mg/kg), or sterile water orally over 2 weeks and cutaneous allodynia was evaluated regularly in the periorbital and hindpaw regions using von Frey filaments. Testing continued until mechanosensitivity returned to baseline levels. Rats were then submitted to bright light stress (BLS) or nitric oxide (NO) donor administration and were again evaluated for cutaneous allodynia in the periorbital and hindpaw regions hourly for 5 hours. RESULTS: Both lasmiditan and sumatriptan exhibited comparable levels of drug-induced cutaneous allodynia in both the periorbital and hindpaw regions, which resolved after cessation of drug administration. Both lasmiditan and sumatriptan pre-treatment resulted in cutaneous allodynia that was evoked by either BLS or NO donor. CONCLUSIONS: In a pre-clinical rat model of MOH, oral lasmiditan, like sumatriptan, induced acute transient cutaneous allodynia in the periorbital and hindpaw regions that after resolution could be re-evoked by putative migraine triggers. These results suggest that lasmiditan has the capacity to induce MOH through persistent latent peripheral and central sensitization mechanisms.


Assuntos
Analgésicos/toxicidade , Benzamidas/toxicidade , Transtornos da Cefaleia Secundários/induzido quimicamente , Hiperalgesia/induzido quimicamente , Piperidinas/toxicidade , Piridinas/toxicidade , Agonistas do Receptor de Serotonina/toxicidade , Animais , Sensibilização do Sistema Nervoso Central/efeitos dos fármacos , Modelos Animais de Doenças , Ratos , Ratos Sprague-Dawley , Sumatriptana/toxicidade
2.
Turk Neurosurg ; 29(1): 106-109, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-29806076

RESUMO

AIM: To investigate the impact of rizatriptan on neural tube development using early chick embryos as a model organism. MATERIAL AND METHODS: A total of 36 pathogen-free Leghorn chicken eggs were selected and categorized in three groups: sham, therapeutic, and supra-therapeutic. After 24 hours, the eggs were opened and injected with sterile drugs, and then reclosed using plastic tape. After a period of 72 hours, the eggs were opened and assessed using the Hamburger-Hamilton chick embryology classification method. TUNEL staining was used to identify apoptosis, and hematoxylin-eosin staining was used to investigate neural tube closure. RESULTS: Treatment with rizatriptan significantly slowed down neural tube development. The supra-therapeutic group showed neural tube closure defects. CONCLUSION: Rizatriptan had a negative effect on neural tube closure. Further research is needed to identify a safe and effective drug for treating migraines during pregnancy.


Assuntos
Desenvolvimento Embrionário/efeitos dos fármacos , Defeitos do Tubo Neural/induzido quimicamente , Tubo Neural/efeitos dos fármacos , Agonistas do Receptor de Serotonina/toxicidade , Triazóis/toxicidade , Triptaminas/toxicidade , Animais , Embrião de Galinha , Galinhas , Tubo Neural/embriologia
3.
Life Sci ; 209: 357-369, 2018 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-30067941

RESUMO

Designer drugs are synthetically formulated to mimic the psychostimulatory effects of an original controlled/illegal drug of abuse. Designer drugs have similar chemical structure or functional analog as compared to existing controlled psychostimulatory drugs. There is a substantial rise in the production and use of designer drugs globally. Piperazine designer drugs were synthesized as an alternative to MDMA and have shown to induce numerous toxic effects leading to huge health, safety, law enforcement & monetary problems, and lethality. Currently, there are very few studies on the dopaminergic neurotoxicity of 1-(3-trifluoromethylphenyl) piperazine (3-TFMPP) and its derivatives (structural congeners). N27 rat dopaminergic neurons are valid cells to investigate the neurotoxic effects and establish the neurotoxic mechanisms of various substances. In the current study, we studied the time and dose-dependent neurotoxicity mechanisms of dopaminergic neurotoxicity of 3-TFMPP (parent compound) and its derivatives (2-TFMPP, 4-TFMPP). TFMPP derivatives-induced significant neurotoxicity (induced dopaminergic neuronal death. TFMPP derivatives-induced oxidative stress, mitochondrial dysfunction, apoptosis and decreased tyrosine hydroxylase expression. If the use of designer drugs are not strictly regulated and restricted around the world, this can lead to numerous central and peripheral disorders leading to a liability to the current and future society.


Assuntos
Apoptose/efeitos dos fármacos , Neurônios Dopaminérgicos/patologia , Mitocôndrias/patologia , Síndromes Neurotóxicas/patologia , Estresse Oxidativo/efeitos dos fármacos , Piperazinas/química , Piperazinas/toxicidade , Animais , Células Cultivadas , Dopamina/metabolismo , Neurônios Dopaminérgicos/efeitos dos fármacos , Neurônios Dopaminérgicos/metabolismo , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Síndromes Neurotóxicas/etiologia , Síndromes Neurotóxicas/metabolismo , Ratos , Agonistas do Receptor de Serotonina/química , Agonistas do Receptor de Serotonina/toxicidade , Tirosina 3-Mono-Oxigenase/metabolismo
4.
Pain ; 159(10): 1980-1988, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29794878

RESUMO

We attempted to gather information on the pathogenesis of medication-overuse headache, as well as on the neurochemical mechanisms through which symptomatic medication overuse concurs to headache chronification. Transcriptional profiles were therefore evaluated as an index of the homeostasis of the trigeminovascular system in the trigeminal ganglion of female rats exposed for 1 month to daily oral doses of eletriptan or indomethacin. We report that both drug treatments change trigeminal ganglion gene expression to a similar extend. Of note, qualitative transcriptomic analysis shows that eletriptan and indomethacin prompt nearly identical, increased expression of genes coding for proteins involved in migraine pathogenesis and central pain sensitization such as neuropeptides, their cognate receptors, prostanoid, and nitric oxide-synthesizing enzymes, as well as TRP channels. These genes, however, were not affected in thoracic dorsal root ganglia. Of note, lowering of orofacial nociceptive thresholds, as well as forepaw hyperalgesia occurred in both indomethacin- and eletriptan-treated rats. Our study reveals that chronic rat exposure to 2 acute headache medications with completely different mechanisms of action prompts pain sensitization with highly similar induction of pronociceptive genes selectively within the trigeminal ganglion. Data further our understanding of medication-overuse headache pathogenesis and provide hints for specific mechanism-based treatment options.


Assuntos
Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Perfilação da Expressão Gênica , Transtornos da Cefaleia Secundários/patologia , Transtornos da Cefaleia Secundários/fisiopatologia , Limiar da Dor/fisiologia , Gânglio Trigeminal/metabolismo , Animais , Anti-Inflamatórios não Esteroides/toxicidade , Modelos Animais de Doenças , Feminino , Expressão Gênica/efeitos dos fármacos , Transtornos da Cefaleia Secundários/induzido quimicamente , Hiperalgesia/radioterapia , Indometacina/toxicidade , Análise de Sequência com Séries de Oligonucleotídeos , Limiar da Dor/efeitos dos fármacos , Pirrolidinas/toxicidade , Ratos , Ratos Wistar , Agonistas do Receptor de Serotonina/toxicidade , Fatores de Tempo , Triptaminas/toxicidade
5.
J Ethnopharmacol ; 219: 23-30, 2018 Jun 12.
Artigo em Inglês | MEDLINE | ID: mdl-29545208

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Cananga odorata essential oil, known as ylang-ylang essential oil (YYO), was commonly used in the aromatherapy for relaxation and mood adjusting use. In our previous study, YYO played anxiolytic effects on the mice in several behavioral tests that based on the instinctive responses to novel environments. AIM OF THE STUDY: To investigate the effects and mechanisms of YYO reversing the anxiety induced by 5-HT2C receptor agonist 1-(3-chlorophenyl) piperazine (m-CPP). MATERIALS AND METHODS: m-CPP was administrated to the male ICR mice to develop an anxiety model. The anxiolytic effect of YYO (0.1%, 1% and 10%, v/v) was evaluated in the elevated plus maze (EPM) test after odor exposure. Western blot was used to detect the phosphorylation levels of extracellular signal-regulated kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB) and the expression of c-Fos in the prefrontal cortex (PFC) and hippocampus after the EPM test. Serotonin and its metabolite change in the brain were detected by liquid chromatogram with an electrochemical detector. The effect of YYO on the plasma corticosterone level was evaluated using enzyme-linked immunosorbent assay (ELISA) after the odor exposure. RESULTS: The behavior analysis showed that m-CPP (2 mg/kg and 4 mg/kg) could induce anxiety behaviors in the mice while diazepam (2 mg/kg) reversed the anxiety behavior induced by m-CPP. YYO dose-dependently increased the time and number of entries in the open arms (p < 0.05) compared to the Tween 80 group. YYO reduced the phosphorylation levels of ERK1/2 (p < 0.05) in both PFC and hippocampus. Down-regulations of phosphor-CREB (p < 0.05) and c-Fos (p < 0.05) were only observed in the hippocampus. YYO also affected the brain serotonin metabolism and reduced the blood plasma corticosterone level of the m-CPP treated mice. CONCLUSION: YYO odor exposure could reverse the anxiety behaviors generated by m-CPP. The anxiolytic effect of YYO was associated with the ERK1/2/CREB pathway in the hippocampus and relevant to the serotonin system.


Assuntos
Ansiolíticos/administração & dosagem , Ansiedade/tratamento farmacológico , Cananga , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Piperazinas/toxicidade , Agonistas do Receptor de Serotonina/toxicidade , Administração por Inalação , Animais , Ansiolíticos/isolamento & purificação , Ansiedade/induzido quimicamente , Ansiedade/metabolismo , Relação Dose-Resposta a Droga , Sistema de Sinalização das MAP Quinases/fisiologia , Masculino , Camundongos , Camundongos Endogâmicos ICR , Óleos Voláteis/isolamento & purificação , Óleos Voláteis/farmacologia , Óleos Voláteis/uso terapêutico , Óleos de Plantas/administração & dosagem , Óleos de Plantas/isolamento & purificação , Serotonina/metabolismo
6.
Neuroscience ; 317: 173-83, 2016 Mar 11.
Artigo em Inglês | MEDLINE | ID: mdl-26701293

RESUMO

The serotonergic system has often been defined as a neuromodulator system, and is specifically involved in learning and memory via its various receptors. Serotonin is involved in many of the same processes affected by cannabinoids. The present study investigated the influence of bilateral post-training intra-prelimbic (PL) administrations of serotonergic 5-hydroxytryptamine type-3 (5-HT3) receptor agents on arachidonylcyclopropylamide (ACPA) (cannabinoid CB1 receptor agonist)-induced amnesia, using the step-through inhibitory avoidance (IA) task to assess memory in adult male Sprague-Dawley rats. The results indicated that sole intra-PL microinjection of ACPA (0.1 and 0.5 µg/rat) and 5-HT3 serotonin receptor agonist (m-Chlorophenylbiguanide hydrochloride, m-CPBG; 0.001, 0.01 and 0.1 µg/rat) impaired, whereas Y-25130 (a selective 5-HT3 serotonin receptor antagonist; 0.001 and 0.01 and 0.1 µg/rat) did not alter IA memory consolidation, by itself. Moreover, intra-PL administration of subthreshold dose of m-CPBG (0.0005 µg/rat) potentiated, while Y-25130 (0. 1 µg/rat) restored ACPA-induced memory consolidation deficit. The isobologram analysis showed that there is a synergistic effect between ACPA and m-CPBG on memory consolidation deficit. These findings suggest that 5-HT3 receptor mechanism(s), at least partly, play(s) a role in modulating the effect of ACPA on memory consolidation in the PL area.


Assuntos
Córtex Cerebral/fisiologia , Transtornos da Memória/metabolismo , Receptor CB1 de Canabinoide/metabolismo , Receptores 5-HT3 de Serotonina/metabolismo , Animais , Ácidos Araquidônicos/toxicidade , Aprendizagem da Esquiva/efeitos dos fármacos , Biguanidas/toxicidade , Compostos Bicíclicos Heterocíclicos com Pontes/uso terapêutico , Agonistas de Receptores de Canabinoides/toxicidade , Córtex Cerebral/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Masculino , Transtornos da Memória/induzido quimicamente , Transtornos da Memória/tratamento farmacológico , Atividade Motora/efeitos dos fármacos , Oxazinas/uso terapêutico , Ratos , Ratos Sprague-Dawley , Tempo de Reação/efeitos dos fármacos , Antagonistas da Serotonina/toxicidade , Agonistas do Receptor de Serotonina/toxicidade
7.
Psychopharmacology (Berl) ; 233(1): 57-70, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26423528

RESUMO

RATIONALE: Serotonin-1B receptor (5-HT1BR) agonist treatment induces obsessive-compulsive disorder (OCD)-like behaviors including locomotor stereotypy, prepulse inhibition deficits, and delayed alternation disruptions, which are selectively prevented by clinically effective OCD treatment. However, the role of 5-HT1BRs in modulating other repetitive behaviors or OCD-like patterns of brain activation remains unclear. OBJECTIVES: We assessed the effects of 5-HT1BR agonism on digging, grooming, and open field behaviors in mice. We also quantified effects on neuronal activation in brain regions overactivated in OCD. Finally, we assessed whether effects of the 5-HT1BR challenge could be blocked by clinically effective, but not ineffective, drug treatments. METHODS: Mice were tested in open field, dig, and splash tests after acute treatment with saline, 1, 3, 5, or 10 mg/kg RU24969 (5-HT1B/1A agonist). Behavioral effects of RU24969 were also tested following co-treatment with vehicle, 1 mg/kg WAY100635 (5-HT1A antagonist) and 5 or 10 mg/kg GR127935 (5HT1B/D antagonist). Separate mice were behaviorally assessed following chronic pretreatment with vehicle with 10 mg/kg fluoxetine or 20 mg/kg desipramine and acute treatment with saline or 10 mg/kg RU24969. Brains were analyzed for Fos expression in the orbitofrontal cortex, the dorsal striatum, and the cerebellum. RESULTS: RU24969 induced robust locomotor stereotypy and decreased rearing, digging, and grooming. Effects were blocked by GR127935 but not by WAY100635. RU24969 also increased Fos expression in the dorsal striatum. Chronic fluoxetine, but not desipramine, alleviated 5-HT1BR-induced effects. CONCLUSIONS: We report novel 5-HT1BR-induced behaviors and striatal activation that were alleviated only by clinically effective pharmacological OCD treatment. Studying the mechanisms underlying these effects could provide insight into OCD pathophysiology.


Assuntos
Corpo Estriado/metabolismo , Transtorno Obsessivo-Compulsivo/tratamento farmacológico , Transtorno Obsessivo-Compulsivo/metabolismo , Antagonistas do Receptor 5-HT1 de Serotonina/uso terapêutico , Agonistas do Receptor de Serotonina/toxicidade , Comportamento Estereotipado/fisiologia , Animais , Corpo Estriado/efeitos dos fármacos , Desipramina/farmacologia , Comportamento Exploratório/efeitos dos fármacos , Comportamento Exploratório/fisiologia , Feminino , Fluoxetina/farmacologia , Indóis/toxicidade , Camundongos , Camundongos Endogâmicos C57BL , Transtorno Obsessivo-Compulsivo/induzido quimicamente , Receptor 5-HT1B de Serotonina/metabolismo , Agonistas do Receptor 5-HT1 de Serotonina/farmacologia , Antagonistas do Receptor 5-HT1 de Serotonina/farmacologia , Comportamento Estereotipado/efeitos dos fármacos , Resultado do Tratamento
10.
J Neurosci Methods ; 251: 151-7, 2015 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-26051553

RESUMO

We developed a novel method to evaluate the nest-building behavior of mice using an inexpensive depth camera. The depth camera clearly captured nest-building behavior. Using three-dimensional information from the depth camera, we obtained objective features for assessing nest-building behavior, including "volume," "radius," and "mean height". The "volume" represents the change in volume of the nesting material, a pressed cotton square that a mouse shreds and untangles in order to build its nest. During the nest-building process, the total volume of cotton fragments is increased. The "radius" refers to the radius of the circle enclosing the fragments of cotton. It describes the extent of nesting material dispersion. The "radius" averaged approximately 60mm when a nest was built. The "mean height" represents the change in the mean height of objects. If the nest walls were high, the "mean height" was also high. These features provided us with useful information for assessment of nest-building behavior, similar to conventional methods for the assessment of nest building. However, using the novel method, we found that JF1 mice built nests with higher walls than B6 mice, and B6 mice built nests faster than JF1 mice. Thus, our novel method can evaluate the differences in nest-building behavior that cannot be detected or quantified by conventional methods. In future studies, we will evaluate nest-building behaviors of genetically modified, as well as several inbred, strains of mice, with several nesting materials.


Assuntos
Imageamento Tridimensional/métodos , Microfilmagem/métodos , Comportamento de Nidação/efeitos dos fármacos , Animais , Compostos Bicíclicos com Pontes/toxicidade , Modelos Animais de Doenças , Masculino , Metilaminas/toxicidade , Camundongos , Camundongos Endogâmicos C57BL , Microfilmagem/instrumentação , Agonistas do Receptor de Serotonina/toxicidade
11.
Respir Physiol Neurobiol ; 212-214: 9-19, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25850079

RESUMO

The preBötzinger (preBötC) complex has been suggested as the primary site where systemically administered selective serotonin agonists have been shown to reduce or prevent opioid-induced depression of breathing. However, this hypothesis has not been tested pharmacologically in vivo. This study sought to determine whether 5-HT1A receptors within the preBötC and ventral respiratory column (VRC) mediate the tachypneic response induced by intravenous (IV) (±)-8-Hydroxy-2-diproplyaminotetralin hydrobromide (8-OH-DPAT) in a decerebrated dog model. IV 8-OH-DPAT (19 ± 2 µg/kg) reduced both inspiratory (I) and expiratory (E) durations by ∼ 40%, but had no effect on peak phrenic activity (PPA). Picoejection of 1, 10, and 100 µM 8-OH-DPAT on I and E preBötC neurons produced dose-dependent decreases up to ∼ 40% in peak discharge. Surprisingly, microinjections of 8-OH-DPAT and 5-HT within the VRC from the obex to 9 mm rostral had no effect on timing and PPA. These results suggest that the tachypneic effects of IV 8-OH-DPAT are due to receptors located outside of the areas we studied.


Assuntos
Bulbo/metabolismo , Receptor 5-HT1A de Serotonina/metabolismo , Respiração , Taquipneia/patologia , 8-Hidroxi-2-(di-n-propilamino)tetralina/toxicidade , Potenciais de Ação/efeitos dos fármacos , Análise de Variância , Animais , Modelos Animais de Doenças , Cães , Relação Dose-Resposta a Droga , Feminino , Masculino , Bulbo/citologia , Bulbo/efeitos dos fármacos , Microinjeções , Neurônios/efeitos dos fármacos , Nervo Frênico/efeitos dos fármacos , Nervo Frênico/fisiologia , Respiração/efeitos dos fármacos , Serotonina/farmacologia , Agonistas do Receptor de Serotonina/toxicidade , Taquipneia/induzido quimicamente
12.
Neuropharmacology ; 93: 179-90, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25698528

RESUMO

We recently reported on the characterization of the hallucinogen 2,5-dimethoxy-4-methylamphetamine's (DOI) ability to elicit a head twitch response (HTR) in DBA/2J mice and the ability of D2 vs. D3 dopamine receptor selective compounds to modulate that response. For these studies, the ability of D3 vs. D2 dopamine receptor selective compounds to attenuate the DOI-dependent HTR was examined. WC 10, a D3 dopamine receptor weak partial agonist with 40-fold binding selectivity for D3 vs. D2 dopamine receptors, produced a dose-dependent decrease in the DOI-induced HTR (IC50 = 3.7 mg/kg). WC 44, a D3 receptor selective full agonist, also inhibited the DOI-induced HTR (IC50 = 5.1 mg/kg). The effect of two D3 receptor selective partial agonists, LAX-4-136 and WW-III-55, were also evaluated. These analogs exhibit 150-fold and 800-fold D3 vs. D2 binding selectivity, respectively. Both compounds inhibited the HTR with similar potency but with different maximum efficacies. At 10 mg/kg WW-III-55 inhibited the HTR by 95%, while LAX-4-136 administration resulted in a 50% reduction. In addition, DOI (5 mg/kg) was administered at various times after LAX-4-136 or WW-III-55 administration to compare the duration of action. The homopiperazine analog LAX-4-136 exhibited greater stability. An assessment of our test compounds on motor performance and coordination was performed using a rotarod test. None of the D3 dopamine receptor selective compounds significantly altered latency to fall, suggesting that these compounds a) did not attenuate the DOI-dependent HTR due to sedative or adverse motor effects and b) may have antipsychotic/antihallucinogenic activity.


Assuntos
Agonistas de Dopamina/uso terapêutico , Movimentos da Cabeça/efeitos dos fármacos , Transtornos dos Movimentos/tratamento farmacológico , Receptores de Dopamina D3/metabolismo , 2,5-Dimetoxi-4-Metilanfetamina/toxicidade , Animais , Azepinas/química , Azepinas/farmacologia , Azepinas/uso terapêutico , Benzamidas/química , Benzamidas/farmacologia , Benzamidas/uso terapêutico , Linhagem Celular Transformada , Agonistas de Dopamina/química , Antagonistas de Dopamina/química , Antagonistas de Dopamina/farmacologia , Agonismo Parcial de Drogas , Humanos , Concentração Inibidora 50 , Masculino , Camundongos , Camundongos Endogâmicos DBA , Atividade Motora/efeitos dos fármacos , Transtornos dos Movimentos/etiologia , Piperazinas/química , Piperazinas/farmacologia , Piperazinas/uso terapêutico , Ligação Proteica/efeitos dos fármacos , Receptores de Dopamina D3/agonistas , Agonistas do Receptor de Serotonina/toxicidade
13.
Artigo em Inglês | MEDLINE | ID: mdl-25445020

RESUMO

QT interval of the electrocardiogram (ECG) is a measure of the duration of the ventricular depolarization and repolarization. In humans, prolongation of the QT interval is a known clinical risk factor for the development of ventricular arrhythmias including 'Torsades de Pointes' and possible sudden cardiac death. After oral administration, fluoxetine (FLX), as well as other selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors can affect cardiac autonomic control, including the QT interval. However, the action of centrally administered FLX on the QT interval has never been explored. Consequently, using the unanesthetized trout as an animal model, we sought to compare the effects of intracerebroventricular (i.c.v.) injection of FLX (5, 15 or 25 µg) on the QT interval of the ECG with the effects observed following i.c.v. injection of 5-HT (0.05, 0.5 or 5 nmol). The QT interval was corrected for the R­R interval. The highest doses of centrally administered FLX and 5-HT induced a prolongation of the corrected QT (QTc) interval reaching a maximum value of 5­10 min after injection (+8% and +6% respectively, P < 0.05). The intra-arterial (i.a.) injections of 5-HT and FLX were without significant effect on the QTc. The i.a. injection of blockers of the autonomic nervous system indicated that the sympathetic nervous system modulated the QTc interval. In conclusion, our data demonstrate that for the first time in any animal species, cardiac electrophysiology is sensitive to central 5-HT and that FLX within the brain may disrupt the autonomic control of ventricular repolarization.


Assuntos
Arritmias Cardíacas/veterinária , Eletrocardiografia/efeitos dos fármacos , Fluoxetina/farmacologia , Oncorhynchus mykiss/fisiologia , Serotonina/farmacologia , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/farmacologia , Animais , Arritmias Cardíacas/induzido quimicamente , Vias de Administração de Medicamentos , Feminino , Doenças dos Peixes/induzido quimicamente , Fluoxetina/administração & dosagem , Masculino , Serotonina/administração & dosagem , Agonistas do Receptor de Serotonina/toxicidade , Inibidores Seletivos de Recaptação de Serotonina/toxicidade , Sotalol/administração & dosagem , Sotalol/farmacologia
14.
Brain Res Bull ; 109: 39-45, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25290207

RESUMO

The dorsomedial hypothalamus (DMH) has long been associated with the regulation of escape, a panic-related defensive response. Previous evidence has shown that the activation of serotonin (5-HT) 1A and 2A receptors impairs escape behavior induced by the electrical stimulation of the same region. In this study we further explore the relationship of the DMH with defense by investigating the effects of 5-HT1A activation on escape behavior generated in male Wistar rats by an ethologically based aversive stimuli, exposure to one of the open arms of the elevated T-maze (ETM). Aside from escape, the ETM also allows the measurement of inhibitory avoidance, a defensive response associated with generalized anxiety disorder. To evaluate locomotor activity, after ETM measurements animals were submitted to an open field. Results showed that intra-DMH administration of the 5-HT1A receptor agonist 8-OH-DPAT inhibited escape expression. Local administration of the 5-HT1A antagonist WAY-100635 by its own was ineffective, but blocked the panicolytic-like effect of 8-OH-DPAT. Chronic (21 days) systemic treatment with imipramine potentiated the anti-escape effect of 8-OH-DPAT. No significant effects of treatment with 8-OH-DPAT or imipramine on avoidance latencies or the number of lines crossed in the open field were found. These results indicate that 5-HT1A receptors within the DMH may play a phasic inhibitory role on ETM escape expression. As previously proposed, facilitation of 5-HT1A-mediated neurotransmission in the DMH may be involved in the mechanism of action of anti-panic compounds.


Assuntos
Núcleo Hipotalâmico Dorsomedial/metabolismo , Aprendizagem em Labirinto/fisiologia , Transtorno de Pânico/diagnóstico , Transtorno de Pânico/fisiopatologia , Receptor 5-HT1A de Serotonina/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralina/toxicidade , Análise de Variância , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Modelos Animais de Doenças , Núcleo Hipotalâmico Dorsomedial/efeitos dos fármacos , Reação de Fuga/efeitos dos fármacos , Comportamento Exploratório/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Microinjeções , Transtorno de Pânico/induzido quimicamente , Piperazinas/farmacologia , Piridinas/farmacologia , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos , Antagonistas da Serotonina/farmacologia , Agonistas do Receptor de Serotonina/toxicidade
15.
Mol Pain ; 10: 35, 2014 Jun 09.
Artigo em Inglês | MEDLINE | ID: mdl-24913307

RESUMO

BACKGROUND: It has been recently recognized that the descending serotonin (5-HT) system from the rostral ventromedial medulla (RVM) in the brainstem and the 5-HT3 receptor subtype in the spinal dorsal horn are involved in enhanced descending pain facilitation after tissue and nerve injury. However, the mechanisms underlying the activation of the 5-HT3 receptor and its contribution to facilitation of pain remain unclear. RESULTS: In the present study, activation of spinal 5-HT3 receptors by intrathecal injection of a selective 5-HT3 receptor agonist SR 57227 induced spinal glial hyperactivity, neuronal hyperexcitability and pain hypersensitivity in rats. We found that there was neuron-to-microglia signaling via the chemokine fractalkine, microglia to astrocyte signaling via cytokine IL-18, astrocyte to neuronal signaling by IL-1ß, and enhanced activation of NMDA receptors in the spinal dorsal horn. Glial hyperactivation in spinal dorsal horn after hindpaw inflammation was also attenuated by molecular depletion of the descending 5-HT system by intra-RVM Tph-2 shRNA interference. CONCLUSIONS: These findings offer new insights into the cellular and molecular mechanisms at the spinal level responsible for descending 5-HT-mediated pain facilitation during the development of persistent pain after tissue and nerve injury. New pain therapies should focus on prime targets of descending facilitation-induced glial involvement, and in particular the blocking of intercellular signaling transduction between neurons and glia.


Assuntos
Hiperalgesia/patologia , Neuroglia/fisiologia , Neurônios/fisiologia , Percepção da Dor/fisiologia , Transdução de Sinais/fisiologia , Medula Espinal/metabolismo , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Regulação da Expressão Gênica/efeitos dos fármacos , Proteína Glial Fibrilar Ácida/metabolismo , Hiperalgesia/induzido quimicamente , Inflamação/induzido quimicamente , Inflamação/complicações , Masculino , Neuralgia/tratamento farmacológico , Neuralgia/etiologia , Neuroglia/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Percepção da Dor/efeitos dos fármacos , Piperidinas/toxicidade , Ratos , Ratos Sprague-Dawley , Antagonistas da Serotonina/uso terapêutico , Agonistas do Receptor de Serotonina/toxicidade , Transdução de Sinais/efeitos dos fármacos , Medula Espinal/citologia , Medula Espinal/efeitos dos fármacos , Nervos Espinhais/lesões
16.
Am J Respir Cell Mol Biol ; 51(1): 77-85, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24484440

RESUMO

The persistence of airway hyperresponsiveness (AHR) and serotonergic enhancement of airway smooth muscle (ASM) contraction induced by ozone (O3) plus allergen has not been evaluated. If this mechanism persists after a prolonged recovery, it would indicate that early-life exposure to O3 plus allergen induces functional changes predisposing allergic individuals to asthma-related symptoms throughout life, even in the absence of environmental insult. A persistent serotonergic mechanism in asthma exacerbations may offer a novel therapeutic target, widening treatment options for patients with asthma. The objective of this study was to determine if previously documented AHR and serotonin-enhanced ASM contraction in allergic monkeys exposed to O3 plus house dust mite allergen (HDMA) persist after prolonged recovery. Infant rhesus monkeys sensitized to HDMA were exposed to filtered air (FA) (n = 6) or HDMA plus O3 (n = 6) for 5 months. Monkeys were then housed in a FA environment for 30 months. At 3 years, airway responsiveness was assessed. Airway rings were then harvested, and ASM contraction was evaluated using electrical field stimulation with and without exogenous serotonin and serotonin-subtype receptor antagonists. Animals exposed to O3 plus HDMA exhibited persistent AHR. Serotonin exacerbated the ASM contraction in the exposure group but not in the FA group. Serotonin subtype receptors 2, 3, and 4 appear to drive the response. Our study shows that AHR and serotonin-dependent exacerbation of cholinergic-mediated ASM contraction induced by early-life exposure to O3 plus allergen persist for at least 2.5 years and may contribute to a persistent asthma phenotype.


Assuntos
Alérgenos/imunologia , Antígenos de Dermatophagoides/imunologia , Asma/imunologia , Modelos Animais de Doenças , Sistema Respiratório/imunologia , Serotonina/toxicidade , Alérgenos/toxicidade , Animais , Asma/induzido quimicamente , Asma/patologia , Criança , Progressão da Doença , Humanos , Macaca mulatta , Contração Muscular/efeitos dos fármacos , Contração Muscular/imunologia , Hipersensibilidade Respiratória/induzido quimicamente , Hipersensibilidade Respiratória/imunologia , Hipersensibilidade Respiratória/patologia , Sistema Respiratório/efeitos dos fármacos , Sistema Respiratório/patologia , Agonistas do Receptor de Serotonina/toxicidade
17.
Behav Pharmacol ; 25(1): 71-9, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24257436

RESUMO

Two experiments examined probiotic pretreatment (Lactobacillus rhamnosus GG) on obsessive-compulsive disorder (OCD)-like behavior induction by RU 24969 in BALB/cJ house mice. In the first experiment, two groups were defined by their daily pretreatment by oral gavage of either (a) L. rhamnosus (1×109 CFU/day) or (b) the saline vehicle. Both a 2- and 4-week probiotic pretreatment attenuated OCD-like behavior induction (increased perseverative open-field locomotion, stereotypic turning, and marble burying) relative to saline pretreatment. Experiment 2 re-examined the 2-week probiotic pretreatment while also comparing it to a 4-week fluoxetine pretreatment. Again, groups were defined by daily pretreatment of either (a) L. rhamnosus for 2 weeks, (b) the saline vehicle for 2 weeks, or (c) fluoxetine (10 mg/kg) for 4 weeks. Pretreatment by either L. rhamnosus or fluoxetine blocked the induction of OCD-like behavior compared with saline pretreatment. Thus the 2-week probiotic pretreatment was again effective. Although side effects of fluoxetine or L. rhamnosus on androgen-dependent behaviors could not be demonstrated, L. rhamnosus treatment appeared comparable to fluoxetine treatment in attenuating mouse OCD-like behaviors.


Assuntos
Suplementos Nutricionais , Transtorno Obsessivo-Compulsivo/tratamento farmacológico , Probióticos/uso terapêutico , Animais , Antidepressivos de Segunda Geração/uso terapêutico , Modelos Animais de Doenças , Comportamento Exploratório/efeitos dos fármacos , Fluoxetina/uso terapêutico , Liofilização , Indóis/toxicidade , Lactobacillus/química , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Atividade Motora/efeitos dos fármacos , Transtorno Obsessivo-Compulsivo/induzido quimicamente , Agonistas do Receptor de Serotonina/toxicidade , Comportamento Social , Fatores de Tempo , Vocalização Animal/efeitos dos fármacos
18.
J Neurosci ; 33(20): 8678-88, 2013 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-23678112

RESUMO

Numerous studies link decreased serotonin metabolites with increased impulsive and aggressive traits. However, although pharmacological depletion of serotonin is associated with increased aggression, interventions aimed at directly decreasing serotonin neuron activity have supported the opposite association. Furthermore, it is not clear if altered serotonin activity during development may contribute to some of the observed associations. Here, we used two pharmacogenetic approaches in transgenic mice to selectively and reversibly reduce the firing of serotonin neurons in behaving animals. Conditional overexpression of the serotonin 1A receptor (Htr1a) in serotonin neurons showed that a chronic reduction in serotonin neuron firing was associated with heightened aggression. Overexpression of Htr1a in adulthood, but not during development, was sufficient to increase aggression. Rapid suppression of serotonin neuron firing by agonist treatment of mice expressing Htr1a exclusively in serotonin neurons also led to increased aggression. These data confirm a role of serotonin activity in setting thresholds for aggressive behavior and support a direct association between low levels of serotonin homeostasis and increased aggression.


Assuntos
Potenciais de Ação/fisiologia , Agressão/fisiologia , Inibição Neural/fisiologia , Núcleos da Rafe/citologia , Neurônios Serotoninérgicos/fisiologia , Serotonina/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralina/toxicidade , Potenciais de Ação/efeitos dos fármacos , Potenciais de Ação/genética , Animais , Ansiedade/tratamento farmacológico , Ansiedade/etiologia , Ansiedade/genética , Ansiedade/patologia , Autorradiografia , Distribuição de Qui-Quadrado , Modelos Animais de Doenças , Comportamento Exploratório/fisiologia , Hipotermia/induzido quimicamente , Isótopos de Iodo/farmacocinética , Locomoção/efeitos dos fármacos , Locomoção/genética , Aprendizagem em Labirinto , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Inibição Neural/efeitos dos fármacos , Inibição Neural/genética , Técnicas de Patch-Clamp , Piperazinas/farmacocinética , Piridinas/farmacocinética , Receptor 5-HT1A de Serotonina/genética , Receptor 5-HT1A de Serotonina/metabolismo , Serotoninérgicos/farmacologia , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Agonistas do Receptor de Serotonina/toxicidade , Fatores de Tempo , Triptofano Hidroxilase/genética
19.
Behav Brain Res ; 246: 103-10, 2013 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-23499701

RESUMO

The relevance of 5-HT1A and 5-HT2C receptors of the basolateral nucleus of the amygdala (BLA) in the mediation of anxiety-related defensive responses has long been acknowledged. Whereas strong evidence supports that activation of the latter receptors provokes anxiety, conflicting findings have been reported on the role played by the former binding site. In this study we further investigated the involvement of 5-HT1A receptors (5-HT1A-Rs) in the regulation of anxiety- and panic-related defensive behaviors. The results showed that intra-BLA injection of the 5-HT1A-R agonist 8-OH-DPAT (0.4-16nmol) in male Wistar rats impaired the acquisition of inhibitory avoidance in the elevated T-maze, increased the percentage of time spent in the lit compartment of the light-dark transition model and enhanced the number of punished drinking events in the Vogel conflict test, all changes compatible with an anxiolytic effect. This agonist also impaired escape expression in the elevated T-maze, suggestive of a panicolytic-like effect. 8-OH-DPAT-induced changes in the elevated T-maze and light-dark tests were blocked by previous local administration of the 5-HT1A-R antagonist WAY-100635 (0.37nmol) and were also observed after intra-BLA microinjection of the benzodiazepine receptor agonist midazolam (10-40nmol). Thus, stimulation of 5-HT1A-Rs in the BLA causes both anxiolytic- and panicolytic-like effects, what may have implications for the pathophysiology and treatment of generalized anxiety and panic disorders.


Assuntos
Tonsila do Cerebelo/metabolismo , Ansiedade/metabolismo , Transtorno de Pânico/metabolismo , Receptor 5-HT1A de Serotonina/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralina/toxicidade , Tonsila do Cerebelo/efeitos dos fármacos , Animais , Ansiolíticos/farmacologia , Ansiedade/induzido quimicamente , Adaptação à Escuridão/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Reação de Fuga/efeitos dos fármacos , Comportamento Exploratório/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Microinjeções , Midazolam/farmacologia , Transtorno de Pânico/induzido quimicamente , Piperazinas/farmacologia , Piridinas/farmacologia , Ratos , Ratos Wistar , Antagonistas da Serotonina/farmacologia , Agonistas do Receptor de Serotonina/toxicidade , Privação de Água
20.
Artigo em Inglês | MEDLINE | ID: mdl-23395768

RESUMO

Various clinical studies suggest that many features of OCD are influenced by sex, age and fluctuations in hormonal levels. Animal models have confirmed these differences, and suggest they are mediated by the serotonergic system. We compared the perseveration behavior in a T-maze after the administration of the 5-HT1A agonist, 8-OH-DPAT (2.0 mg/kg) and the preventive action of subchronic fluoxetine (10 mg/kg, 3 times) in middle-aged (11-14 months) males and female rats in two endocrine states: irregular cycles (tested in diestrus) or persistent diestrus. After 8-OH-DPAT, females with persistent diestrus presented higher perseveration scores than males and females with irregular cycles. Fluoxetine produced an anticompulsive-like effect only in females with persistent diestrus. Females in persistent diestrus showed higher estradiol levels than those in irregular cycles or males. In all groups 8-OH-DPAT increased ambulation and fluoxetine did not modify this action. In males, the combined administration of fluoxetine and 8-OH-DPAT impaired motor coordination. Data are discussed on the basis of estradiol levels and sex differences.


Assuntos
Sistema Endócrino/metabolismo , Transtorno Obsessivo-Compulsivo/metabolismo , Transtorno Obsessivo-Compulsivo/prevenção & controle , Caracteres Sexuais , 8-Hidroxi-2-(di-n-propilamino)tetralina/toxicidade , Fatores Etários , Análise de Variância , Animais , Modelos Animais de Doenças , Sistema Endócrino/efeitos dos fármacos , Estradiol/sangue , Comportamento Exploratório/efeitos dos fármacos , Feminino , Fluoxetina/uso terapêutico , Hormônio Foliculoestimulante/metabolismo , Hormônio Luteinizante/metabolismo , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Aprendizagem em Labirinto/fisiologia , Transtorno Obsessivo-Compulsivo/induzido quimicamente , Desempenho Psicomotor/efeitos dos fármacos , Ratos , Teste de Desempenho do Rota-Rod , Agonistas do Receptor de Serotonina/toxicidade , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...